| Ytd | 27.38% | |
| 1y | 7.77% |
| Open | 7.30 | Prev Close | 7.34 | Low | 7.29 | High | 7.73 | Mkt Cap | 158.91M |
| Vol | 59.90K | Avg Vol | 50.10K | EPS | -1.95 | P/E | N/A | Forward P/E | N/A |
| Beta | 1.51 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 9.30 | 200-d Avg | 8.46 | 1yr Est | 0.00 |
MSLE News
Craig-Hallum analyst Adam Vogel initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Bu
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developi
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developi
Shares of Satellos Bioscience Inc. (NASDAQ: MSLE - Get Free Report) have received an average rating
FDA clearance expands development of forazapadin into a second degenerative muscle disease with sign
HC Wainwright & Co. analyst Arthur He reiterates Satellos Bioscience (NASDAQ:MSLE) with a Buy
Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.56) per share which missed the an
HC Wainwright & Co. analyst Arthur He maintains Satellos Bioscience (NASDAQ:MSLE) with a Buy
Recently listed, Satellos Bioscience Inc. (NASDAQ:MSLE) on Wednesday reported six-month interim data
Satellos reports six-month interim data showing SAT-3247 improved muscle composition, maintained str
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday'
Fat fraction mean improvement of 3.7% from 49.7% at TRAILHEAD baseline to 46.0% at month 6, suggesti
Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a cl
TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) ("Sate
TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) ("Satel
HC Wainwright & Co. analyst Arthur He reiterates Satellos Bioscience (NASDAQ:MSLE) with a Buy
Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.53) per share. This is a 20.45 pe
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Satellos Bioscience (NASDAQ:MSLE) w
Pre-Market Stock Futures: Futures are trading mixed as we get ready to kick off the first-quarter ea
HC Wainwright & Co. analyst Arthur He maintains Satellos Bioscience (NASDAQ:MSLE) with a Buy
Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst r
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Satellos Bioscience (NASDAQ:MS